A human laboratory pilot study with baclofen in alcoholic individuals

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Medicine

Background:

• Alcohol dependence (AD) remains a significant public health challenge.
• Current pharmacotherapies for AD have limitations, necessitating novel treatment strategies.
• Baclofen, a GABA(B) receptor agonist, shows preclinical and clinical promise for treating AD.

Purpose of the Study:

• To investigate the biobehavioral mechanisms underlying baclofen's effects on alcohol consumption in individuals with AD.
• To explore potential moderators, including genetic polymorphisms (DRD4, 5-HTTLPR) and individual factors (anxiety, family history), of baclofen's efficacy.
• To assess baclofen's impact on alcohol cue-reactivity and self-administration.

Main Methods:

• A double-blind, randomized, placebo-controlled pilot study involving 14 non-treatment seeking, heavy-drinking individuals with AD.
• Participants received either baclofen (10mg t.i.d.) or an active placebo (cyproheptadine 2mg t.i.d.) for 7 days.
• Alcohol cue-reactivity and alcohol self-administration tasks were conducted, alongside assessments of genetic polymorphisms and clinical factors.

Main Results:

• Baclofen significantly increased subjective feelings of stimulation (p=.001) and sedation (p<.01) in participants.
• A significant reduction in overall alcohol consumption was observed with baclofen treatment (p<.01).
• Baclofen's effects on sedation and reduced drinking were more pronounced in individuals with the DRD4 long allele (DRD4L) and were also moderated by 5-HTTLPR LL genotype.

Conclusions:

• Baclofen's efficacy in reducing alcohol consumption may be linked to its modulation of the biphasic effects of alcohol.
• Genetic factors, specifically DRD4 and 5-HTTLPR polymorphisms, may influence individual responses to baclofen for alcohol dependence.
• Larger-scale studies are warranted to confirm these preliminary findings and elucidate the precise mechanisms of action.